Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2738891rdf:typepubmed:Citationlld:pubmed
pubmed-article:2738891lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0024660lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C1704689lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0002583lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0016410lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0029277lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0039667lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0060626lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:2738891lifeskim:mentionsumls-concept:C0205088lld:lifeskim
pubmed-article:2738891pubmed:issue7lld:pubmed
pubmed-article:2738891pubmed:dateCreated1989-8-4lld:pubmed
pubmed-article:2738891pubmed:abstractTextSix new 5,8-dideaza analogues of folic acid and aminopterin containing a terminal L-ornithine residue were prepared by using multistep synthetic sequences. Each was evaluated as an inhibitor of hog liver folylpolyglutamate synthetase and human dihydrofolate reductase. Structural modifications at positions 2, 4, 5, and 10 were included to help define structure-activity relationships for compounds of this type. The compound N alpha-(4-amino-4-deoxy-5-chloro-5,8-dideazapteroyl)-L-ornithine (3f) was identified as the most potent inhibitor of mammalian folylpolyglutamate synthetase reported thus far (Ki congruent to 2 nM). Its 4-oxy counterpart, N alpha-(5-chloro-5,8-dideazapteroyl)-L-ornithine, was only 5-fold less inhibitory than 3f toward folylpolyglutamate synthetase but was found to be a much weaker inhibitor of dihydrofolate reductase than 3f.lld:pubmed
pubmed-article:2738891pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:languageenglld:pubmed
pubmed-article:2738891pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:citationSubsetIMlld:pubmed
pubmed-article:2738891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2738891pubmed:statusMEDLINElld:pubmed
pubmed-article:2738891pubmed:monthJullld:pubmed
pubmed-article:2738891pubmed:issn0022-2623lld:pubmed
pubmed-article:2738891pubmed:authorpubmed-author:ShaneBBlld:pubmed
pubmed-article:2738891pubmed:authorpubmed-author:SinghS KSKlld:pubmed
pubmed-article:2738891pubmed:authorpubmed-author:FreisheimJ...lld:pubmed
pubmed-article:2738891pubmed:authorpubmed-author:HynesJ BJBlld:pubmed
pubmed-article:2738891pubmed:authorpubmed-author:PatilS ASAlld:pubmed
pubmed-article:2738891pubmed:issnTypePrintlld:pubmed
pubmed-article:2738891pubmed:volume32lld:pubmed
pubmed-article:2738891pubmed:ownerNLMlld:pubmed
pubmed-article:2738891pubmed:authorsCompleteYlld:pubmed
pubmed-article:2738891pubmed:pagination1559-65lld:pubmed
pubmed-article:2738891pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:meshHeadingpubmed-meshheading:2738891-...lld:pubmed
pubmed-article:2738891pubmed:year1989lld:pubmed
pubmed-article:2738891pubmed:articleTitleInhibition of mammalian folylpolyglutamate synthetase and human dihydrofolate reductase by 5,8-dideaza analogues of folic acid and aminopterin bearing a terminal L-ornithine.lld:pubmed
pubmed-article:2738891pubmed:affiliationDepartment of Pharmaceutical Sciences, Medical University of South Carolina, Charleston 29425.lld:pubmed
pubmed-article:2738891pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2738891pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:2738891lld:chembl
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2738891lld:pubmed